SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as investors weigh explosive worldwide AI infrastructure demand and rapid hiring against ongoing concerns regarding legal and governance issues ahead of earnings. The community remains deeply divided, with bulls pointing to the company's critical role in data center buildouts as a major value play, while bears continue to cite leadership volatility and past accounting controversies as primary reasons for caution.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense debate as investors weigh record-breaking revenue and profit growth against concerns regarding its high valuation and reliance on government contracts. While bulls highlight the company's aggressive AI momentum and accelerating U.S. commercial adoption, the community is actively divided between those betting on long-term structural dominance and others warning of a potential post-earnings pullback.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened activity driven by a mix of institutional buying and rumors of strategic foundry partnerships with tech giants, fueling a volatile tug-of-war between bullish sentiment around its potential market leadership and bearish concerns over overextended valuations. The community is actively debating whether these gains represent a sustained structural turnaround or a speculative pump, with many focused on how the stock will perform alongside broader semiconductor sector earnings.

SKK Holdings Ltd. operates as a holding company, which engages in the provision of civil engineering services in subsurface utility works, including power and telecommunication cable laying, water pipeline and sewer rehabilitation works. The company was founded by Chun Seong Ng and Koon Kiat Sze on October 16, 2013 and is headquartered in Singapore.

SKK Holdings Ltd. - Ordinary Shares - Class A

SKK Holdings Ltd

SKK Holdings is experiencing extreme volatility driven by a major drone asset acquisition agreement, with the community polarized between those chasing the low-float momentum and those warning of significant dilution risks. Traders are intensely focused on the stock's thin float and rapid, news-fueled price swings, leading to heated debates regarding whether the stock is a prime candidate for a massive short squeeze or a classic pump-and-dump trap.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing significant volatility driven by investor reactions to the evolving Clarity Act, which aims to establish a regulatory framework for stablecoins. The community is actively debating the stock's potential as a long-term infrastructure play for digital payments versus concerns over regulatory hurdles and high-profile industry hacks.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors debate whether the stock is a deep-value opportunity near decade lows or a declining legacy brand facing existential threats from emerging competitors. While some traders point to insider buying and potential future catalysts like the World Cup to argue for a turnaround, others are aggressively shorting the stock, citing persistent loss of market share, margin compression, and skepticism regarding the effectiveness of current management.

Daddy Darth Vader

The DARTH CRYPTO community is aggressively rallying around a Star Wars-themed pump for May the Fourth, with users actively swapping from other projects to join the movement. Investors are fueling the hype by labeling it a 'daddy' token and emphasizing a transition to a community-driven model following the departure of the original developer.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

Mask Network is gaining significant attention following news of a institutional convertible note agreement, which has traders watching for a potential breakout and squeeze. The community is actively discussing its low-float status and after-hours volume, with many focusing on specific price levels and the broader narrative of its pivot into AI infrastructure.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals is experiencing significant market attention and heightened volatility as retail investors and trading communities track its recent private placement financing, which has sparked intense debate over the company's long-term prospects versus its potential for a short-term squeeze. While momentum traders are actively discussing the stock's low float and aggressive intraday price action, others are expressing strong skepticism, warning of dilution risks and the company's complex history with reverse stock splits.

Skycorp Solar Group Ltd. is a holding company which designs, develops, manufactures and sells solar PV products and solar power system solutions services, through its indirectly wholly owned subsidiary. Its products include One-stop Solar system, Inverter, LFP Battery, Balcony Storage, and PV Cable. It operates through the following segments: Solar PV Products, High Performance Computing Products, and Others. The Solar PV Products segment includes servers, photovoltaic cable, and photovoltaic connectors. The High Performance Computing Products segment refers to the HPC servers and accessories delivered to the customers. The company was founded on January 19, 2022 and is headquartered in Ningbo, China.

Skycorp Solar Group Ltd. - Ordinary Shares - Class A

Skycorp Solar Group Ltd.

Skycorp Solar Group is trending following the announcement of a deal to acquire the remaining stake in Nanjing Cesun Power, paired with a private placement of shares. The community is actively debating the stock's potential for a significant squeeze, focusing on its low float and lock-up periods, while simultaneously weighing the risks of dilution and the company's recent history of volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>BioLineRx partnered with Hemispherian to conduct a trial testing GLIX1 in patients with Glioblastoma.</li><li>Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile.</li><li>BioLineRx is currently testing Motixafortide in a Phase 2b trial for pancreatic cancer.</li></ul>Shares of BioLineRx Ltd. (BLRX) surged 10% in pre-market trading on Tuesday, putting the stock on track to test its 50-day moving average for the first time since early March, after the company hit a significant milestone by dosing the first patient in an early-stage trial of its new cancer therapy.BioLineRx has partnered with Hemispherian AS, a clinical-stage oncology firm, to conduct a trial testing GLIX1 in patients with Glioblastoma and other high-grade brain tumors.Meanwhile, retail sentiment for <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> on Stocktwits remained in the ‘neutral’ territory over the past 24 hours.<h2 class="st-heading-2">Initial Trial Results Expected In 2027</h2>GLIX1 is a first-in-class oral therapy designed to selectively damage cancer cells by restoring TET2 activity, a tumor suppressor gene. This novel approach could provide a new treatment option for aggressive tumors such as Glioblastoma, where effective therapies remain limited, BioLineRx said.Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile. The Phase 1 trial will enroll up to 30 patients to determine a safe dose, with initial results expected in the first half of 2027.“We believe GLIX1 has the potential to offer a novel therapeutic approach in this cancer indication, as well as in multiple other cancer indications, where DNA damage repair is critical for cancer survival,” said Philip Serlin, CEO of BioLineRx.<h2 class="st-heading-2">What Else Is In The Pipeline?</h2>BioLineRx is testing Motixafortide in a Phase 2b trial for pancreatic cancer, combining it with immunotherapy and standard chemotherapy. The study is progressing quickly, with an interim analysis expected later this year.The company is also testing Motixafortide for Sickle Cell Disease (SCD) and gene therapy. A Phase 1 study showed the drug can help mobilize stem cells for gene therapy in sickle cell disease.The stock has shed 22% of its value so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-glnd-stock-crash-to-52-week-low-today/cZB8sI8Re5A">Why Did GLND Stock Crash 30% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months

The biotech firm announced the dosing of its first patient in an early-stage trial of its new cancer therapy.

Equity

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a...

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM...

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx Reports 2025 Financial Results and Provides Corporate Update BioLineRx Reports 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, March 23, 2026 - On track...

Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings

BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.read more...

BioLineRx to Report 2025 Annual Results on March 23, 2026

BioLineRx to Report 2025 Annual Results on March 23, 2026 BioLineRx to Report 2025 Annual Results on March 23, 2026 PR Newswire TEL AVIV, Israel, March 16, 2026 Management to Hold Conference Call at...

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel...

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire TEL AVIV, Israel, Nov. 18, 2025 Management to Hold...

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types BioLineRx Announces Receipt of USPTO Notice of Allowance for Key...

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-new-pilot-phase-data-phase-2-combination">announced</a> positive data from the single-arm pilot phase of its Phase 2 trial evaluating its drug in the treatment of pancreatic cancer.The study is evaluating the company’s Motixafortide, Cemiplimab, and standard-of-care chemotherapies Gemcitabine and Nab-paclitaxel, versus Gemcitabine and Nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Progression-free means that the patient's disease did not get worse or spread.CEO Philip Serlin said that the data emerging from the pilot phase of the study are “extremely encouraging,” while also noting that pancreatic cancer is the “most challenging” tumor to treat.The company also stated that it now plans to enroll 108 patients in the Phase 2 trial, which will be a randomized study, based on the results of the pilot phase. The company had previously planned to enroll only 30 patients in the study.The trial is planned to be fully enrolled in 2027. While the trial's primary endpoint is progression-free survival (PFS), secondary objectives include safety, response rate, disease control rate, duration of clinical benefit, and overall survival.Following the news, Jones Research upgraded BioLineRx to ‘Buy’ from ‘Hold’ with a $12 price target. With these results, BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial, assuming favorable Phase II results, the analyst said.On Stocktwits, retail sentiment around BLRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_12_47_05_PM_png_ca2195fcbe.webp" alt="BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits" width="626" height="68"><figcaption>BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> is down by about 50% this year and by about 84% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-eyeing-hiv-drug-rollout-in-low-income-countries-report/ch0ubVvRbuE">Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

BLRX
BioLineRx, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest BLRX News

BLRXBioLineRx, Ltd.